The SOCE Machinery: An Unbalanced Knowledge between Left and Right Ventricular Pathophysiology

Jessica Sabourin 1,* , Antoine Beauvais 2,3,4,†, Rui Luo 1,‡, David Montani 2,3,4,‡, Jean-Pierre Benitah 1, Bastien Masson 2,3,4,‡ and Fabrice Antigny 2,3,4,‡

1 Signalisation et Physiopathologie Cardiovasculaire, Inserm, Université Paris-Saclay, UMR-S 1180, 91400 Orsay, France
2 Faculté de Médecine, Université Paris-Saclay, 94270 Le Kremlin-Bicêtre, France
3 Hypertension Pulmonaire: Physiopathologie et Innovation Thérapeutique, Hôpital Marie Lannelongue, Université Paris-Saclay, Inserm, UMR-S 999, 92350 Le Plessis-Robinson, France
4 Service de Pneumologie et Soins Intensifs Respiratoires, Centre de Référence de l’Hypertension Pulmonaire, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Bicêtre, 94270 Le Kremlin-Bicêtre, France
* Correspondence: jessica.sabourin@universite-paris-saclay.fr (J.S.); fabrice.antigny@universite-paris-saclay.fr (F.A.); Tel.: +33-(33)-180-006-302 (J.S.); +(33)-140-942-299 (F.A.)
† These authors contributed equally to this work.

Abstract: Right ventricular failure (RVF) is the most important prognostic factor for morbidity and mortality in pulmonary arterial hypertension (PAH) or pulmonary hypertension (PH) caused by left heart diseases. However, right ventricle (RV) remodeling is understudied and not targeted by specific therapies. This can be partly explained by the lack of basic knowledge of RV remodeling. Since the physiology and hemodynamic function of the RV differ from those of the left ventricle (LV), the mechanisms of LV dysfunction cannot be generalized to that of the RV, albeit a knowledge of these being helpful to understanding RV remodeling and dysfunction. Store-operated Ca$^{2+}$ entry (SOCE) has recently emerged to participate in the LV cardiomyocyte Ca$^{2+}$ homeostasis and as a critical player in Ca$^{2+}$ mishandling in a pathological context. In this paper, we highlight the current knowledge on the SOCE contribution to the LV and RV dysfunctions, as SOCE molecules are present in both compartments. The relative lack of studies on RV dysfunction indicates the necessity of further investigations, a significant challenge over the coming years.

Keywords: SOCE; SOCs; TRPCs; Orai1/3; STIM1/2; calcium signaling; left and right hypertrophy; left and right heart failure; pulmonary hypertension

1. Introduction

In pulmonary arterial hypertension (PAH), the elevated pulmonary vascular resistance due to distal pulmonary artery obstruction ultimately induces right ventricular failure (RVF) [1]. Heart failure (HF) describes the inability of a heart to maintain the workload necessary to meet oxygen and nutrient needs. The purpose of the RV is to maintain a sufficient blood flow through the lungs to achieve adequate left ventricular (LV) filling with oxygenated blood. Hence, cardiac output of the right and left heart is closely linked, as a decrease in pulmonary blood flow will decrease LV filling and, consequently, LV cardiac output. As the pulmonary circulation works at a lower pressure than the systemic circulation, the RV wall is much thinner and therefore less powerful, allowing better compliance but poorer adaptation to overload [2]. Thus, any sudden increase in pulmonary vascular resistance or blood volume may overcome the RV’s capacities, provoking a dilatation and then a decrease in stroke volume and cardiac output. If the phenomenon is chronic, the RV can, for a time, as with the LV, respond by progressive hypertrophy to improve its contractility [1,3].
Excessive RV dilatation triggers a tricuspid regurgitation favoring venous congestion, quickly assessed by clinical signs (edema, jugular distension, anasarca, and so on), biochemical markers (elevated NT-proBNP or BNP), and ultrasonography. It also eventually leads to the protrusion of the interventricular septa toward the LV, impairing its filling and contractility. These signs of RV dysfunction are critical predictors of poor prognosis, suggesting an impending HF and a high risk of death by cardiogenic shock [4]. Because pulmonary embolism [5] and pulmonary hypertension (PH) [6] increase RV afterload, they are classic cases of fatal diseases that provoke acute or chronic RVF.

Currently, treatment of RV dysfunction is based on blood volume management, using mainly diuretics to reduce RV overload while carefully avoiding systemic hypotension. In the most severe cases, inotropes and vaspressors may be needed to maintain a sustainable cardiac output [6]. None of these treatments are specific to the RV. Moreover, there is no treatment targeting the RV remodeling during chronic failure, despite being a critical factor in the severity of PH [7].

The RV is a crescent-shaped structure linked to the venous system from one side and the pulmonary circulation from the other, through the tricuspid and the pulmonary valves, respectively. Its free wall is thinner than the LV myocardium (3–5 mm versus around 1 cm) for a volume that is 10–15% greater and a mass one-third to one-sixth smaller [8,9]. Three cardiomyocyte layers are described in the LV, but only two in the RV, with myocytes arranged circumferentially on the external layer and longitudinally in the internal layer. This organization allows a peristalsis-like motion during contraction, whereas the LV systole is torsion-shaped due to oblique myocardial fibers. Notably, the RV has smaller cardiomyocytes at the histological level and contains 30% more collagen [10].

These anatomical features give the RV greater compliance, allowing the venous return variations to absorb and provide a stable stroke volume toward the low-impedance pulmonary circulation while using only one-fourth of the LV stroke work. Subsequently, the RV is more vulnerable to significant increments in pulmonary arterial pressure.

The anatomical differences between the RV and LV are the result of a different embryological origin, developed during the cardiac morphogenesis from the third to the eighth week of gestation. The LV arises from the primitive heart tube, also named the first cardiac field. In contrast, the RV is formed from the anterior part of the “second heart field”, cardiac precursor cells migrating towards the extremities of the primitive heart tube [11]. In the foetus, pulmonary vascular resistance is high; therefore, the RV and LV have equal thickness and power, producing 60% of the cardiac output [12]. This pulmonary pressure normalizes at birth, and the compliance rises as the free wall slims down. The ventricle adopts its final form within the first year.

The nourishing coronary blood flow, supplied by the right coronary artery in 80% of the population, occurs in both diastole and systole (mainly during diastole in the LV) but is more vulnerable to systemic hypotension and intracardiac pressure increase. Nevertheless, the RV’s relative resistance to ischemia is partially explained by lower oxygen consumption and higher oxygen extraction reserve at rest. Moreover, the expression of the anaerobic glycolytic enzyme is higher in RV than in LV cardiomyocytes [13]. Potential gene and protein expression differences between human LV and RV cardiomyocytes have been little explored.

The RV structure and function assessment are also more challenging than the LV. Its retrosternal position and complex geometry complicate echocardiography evaluation. Metabolic imaging is not yet feasible, as the free wall is too thin. Right-heart catheterization is the most accurate tool to measure hemodynamic features, especially to calculate pulmonary vascular resistance, but it is not a routine test. Compared to the LV, RV conductance studies are technically more challenging, partly because of the difficulty of obtaining reliable ventricular volumes without magnetic resistance imaging [2].
2. Ca$^{2+}$ Signaling in the Left and Right Ventricles

The common pathophysiology of LVF and RVF is cellular remodeling, which is regulated and coincides with the remodeling of the intracellular Ca$^{2+}$ concentration ([Ca$^{2+}$]$_i$). Ca$^{2+}$ mishandling is a hallmark of left and right HF [14,15] and is a major cause of cardiac contractile dysfunction. Indeed, Ca$^{2+}$ is a universal signaling ion essential for most cardiomyocyte functions, including excitation-contraction coupling (ECC) and regulation of gene expression. In mammals, controlling [Ca$^{2+}$]$_i$ is fundamental for almost all cellular processes. In the cardiac compartment, the contraction of cardiomyocytes is mainly controlled by the ECC. The depolarization during action potential (AP) activated the L-type Ca$^{2+}$ channels (LTCC). The resulting small Ca$^{2+}$ influx activates massive Ca$^{2+}$ release from the sarcoplasmic reticulum (SR) through the type 2 ryanodine receptor (RyR2): a Ca$^{2+}$-induced Ca$^{2+}$ release (CICR) process that controls contractile myofilaments. Other processes could also participate in cardiomyocyte Ca$^{2+}$ homeostasis, notably the store-operated Ca$^{2+}$ entry (SOCE) as described herein.

3. Generality about the SOCE Machinery

This mechanism refers to the activation of the store-operated channels (SOCs) following endoplasmic/sarcoplasmic reticulum (ER/SR) Ca$^{2+}$ depletion, an important process in modulating [Ca$^{2+}$]$_i$ in most cell types, first described by Putney in 1989 [16]. The transient receptor potential canonical (TRPC) channels were the first plasma membrane channels suspected to contribute to SOCE. TRPC channels are constituted by seven isoforms (TRPC1 to TRPC7, with TRPC2 being a pseudogene in humans), which can form homo- or hetero-tetrameric channels like TRPC1/5, TRPC1/3, TRPC1/4, TRPC3/4, TRPC4/5, and TRPC1/4/5 [17]. The inhibition of TRPC channels by pharmacological or knockdown approaches indicates that TRPC1, C4, and C5 participate to SOCE in several cell types [17–23].

As TRPC channels are non-selective cation (Ca$^{2+}$, Na$^+$, K$^+$) channels, their electrophysiological properties do not match with the highly selective Ca$^{2+}$ current activated by intracellular store depletion, called Ca$^{2+}$ release-activated Ca$^{2+}$ current ($I_{\text{CRAC}}$) [24–26]. Under physiological conditions, the Ca$^{2+}$ selectivity is 1000 times higher than the Na$^+$ permeation. From 2005 to 2006, the two main molecular components of SOCE and the $I_{\text{CRAC}}$ were identified by several teams: the STIM (stromal interaction molecule) protein, which is an ER/SR Ca$^{2+}$ sensor with its N-terminal EF-hand domain; and Orai (also named CRACM), which is the highly Ca$^{2+}$ selective for typical SOCs. Indeed, contrary to TRPC channels, the electrophysiological properties of the Orai1 channel perfectly fit with the native $I_{\text{CRAC}}$, a sustained non-voltage-activated Ca$^{2+}$ inward current with an inward rectification. There are two homologous STIM proteins, called STIM1 and STIM2, each having different variants that have been characterized since the discovery of the protein family. STIM1 has two variants: STIM1 long (STIM1L), which is associated with rapid activation of SOCE only in skeletal myotubes through permanent cluster formation at the plasma membrane with Orai1 [27]; and STIM1B, a neuron-specific variant [28]. The STIM1 homolog, STIM2, has also 2 variants: STIM2.1 (or STIM2β), which is known to have inhibitory activity on SOCE; and the STIM2.2 (or STIM2α), a SOCE stimulator variant [29]. The Orai family comprises three proteins encoded by independent genes: Orai1, Orai2, and Orai3. In most cells studied so far, STIM1 and Orai1 constitute the core machinery of the ubiquitous SOCE pathway.

Following the molecular identification, the SOCE activation mechanism was explained by several studies mainly performed in non-excitable cells. A decrease in the ER/SR Ca$^{2+}$ concentration induces a conformational change that extends the STIM1 cytosolic tail, which then promotes its oligomerization and exposes the CAD/SOAR (CRAC activation domain/STIM-Orai activating region) domain and the lysine-rich tail of STIM1. At the same time, the exposure of the CAD/SOAR domain allows STIM1 to trap Orai1 channels via interactions with their C-terminal cytosolic domain [30–34].
While STIM1/2 constitutes the main regulatory protein for Orai1, mechanisms leading to TRPC channels’ activation are still being investigated. The activation of TRPC channels predominantly occurs downstream of the GPCR-GqPLC and receptor tyrosine kinases, coupled to PLCγ via IP3-dependent Ca2+ release from the ER or DAG production. Ca2+ itself, via calmodulin and other Ca2+-binding proteins or PIP2, are also important regulators of TRPC channels. These multiple mechanisms of TRPC channels’ activation possibly depend on their subunit composition or signaling complex environment. Nonetheless, it has been also reported that STIM1 directly or indirectly interacts with TRPC channels (all except TRPC7), conferring them a SOCE function [35,36]. Moreover, the group of Ambudkar demonstrated that TRPC1 function could also depend on the Orai1-mediated Ca2+ microdomain, which generates the recruitment of TRPC1 into the plasma membrane, which is activated by STIM1.

4. The SOCE in the Ventricles

Since Putney’s work, the existence of SOCE in non-excitable cells has been well known [37]. In 2002, it was reported, for the first time, the presence of SOCE activated by passive and active Ca2+ depletion in neonatal rat cardiomyocytes [38] and embryonic and neonatal mice myocytes [39]. The SOCE was also shown, in neonatal rabbit cardiomyocytes, to regulate the SR Ca2+ load [40]. The presence of this Ca2+ entry has been subsequently repeatedly suggested to be a feature of an immature cardiac system.

In adult mouse cardiomyocytes, SOCE, measured by fluorimetry and patch-clamp, is also detected following the passive SR Ca2+ depletion [41]. However, the huge SOCE amplitude inducing hypercontracture in this report is highly questionable. More recently, Wen and colleagues demonstrated that complete SR Ca2+ depletion is essential to optimally activate moderated SOCE in adult mouse cardiomyocytes [42]. Indeed, it is now widely accepted that the SOCE amplitude in adults is significantly lower than in embryonic and neonatal cardiomyocytes and declines during development [39,43–51]. Moreover, it has been repeatedly reported that only 20–70% of adult cardiomyocytes exhibit SOCE in response to SR Ca2+ depletion [43,48,49,52]. Nonetheless, many reports did not use the appropriate and optimal SR Ca2+ depletion protocol to induce sufficient Ca2+ emptying to activate SOCs [43,44]. For example, Wu and colleagues show that only 20% of the cells present SOCE, but with a protocol mobilizing only inositol trisphosphate receptors (IP3R) and not the RyR2 [43]. In early studies, evidence of SOCE is also suggested using pharmacological inhibitors, such as 2-APB, SKF-96365, BTP2, or inorganic cations, such as Gd2+ and La3+, whose specificity is controversial. Lately, the existence of SOCE in the cardiac tissue was confirmed by the detection of the different isoforms of TRPC1/C3-C7, Orai1–3 channels, and STIM1–2 proteins in the embryonic, neonatal, and adult cardiomyocytes of rats, mice, cats, zebrafish, squirrels, and chickens, as well as in human left myocardial tissue, with an expression that declines after birth [27,40,44,46,51,53–68].

5. The SOCE in the Adverse LV Remodeling

5.1. Role of STIM1

By manipulating their expression, several in vivo studies have demonstrated the active participation of cardiac STIM1/Orai1-mediated SOCE during hypertrophy and HF.

For STIM1, the changes in its expression vary according to the experimental pathological models (Table 1 and Figure 1). The first study by Ohba et al. in 2009 showed no change in expression of STIM1 in a model of compensated hypertrophy by abdominal aortic banding constriction (AAB model) over 4 weeks in rats [57]. Later, in the same experimental model, upregulation of STIM1 with the doubling of SOC current (ISOC) is observed after 14 and 28 days of pressure overload [69]. A second current, independent of the SR Ca2+ load and activated very rapidly, with an inward rectification reflecting an Orai1-mediated current, is also observed under this hypertrophic stress condition. This suggests that STIM1 can activate Orai1 and non-selective cationic channels, like TRPC channels, in adult cardiomyocytes. The rapid activation of this current can be also explained by the constitutive
association between STIM1 or STIM1L and Orai1 at the membrane, as observed in sinoatrial node cells [70]. Luo et al. also demonstrated an increase in STIM1L variant expression, associated with increased SOCE after compensated hypertrophy induced by constriction of the thoracic aorta for 3 weeks in mice, but they did not find any increase in the classic STIM1 variant [46]. After 2 or 4 weeks of pressure overload in mice by the transverse aorta constriction (TAC model), inducing compensated or decompensated hypertrophy, an increase in STIM1 expression is found [61,71]. By contrast, we and others found no changes in STIM1 expression after 2, 5 or 8 weeks of TAC in mice [72,73]. Correll et al. chose to use a mouse model of cardiac specific STIM1 overexpression, thereby mimicking its upregulation, to study its role in the pathology. Under basal conditions, the transgenic STIM1 mice show sudden cardiac death at 6 weeks. The surviving mice develop severe HF, associated with induction of the fetal gene program, histopathology, and mitochondrial structural alterations, at 12 weeks of age [61]. More recently, adult young cats, with compensated hypertrophy induced by ascending aorta banding for 4 months, show increased protein expression of STIM1 [74]. Lastly, after neurohormonal stimulation by Angiotensin II (AngII) over 4 weeks, STIM1 expression is also raised [75]. In human, STIM1 mRNA level is also significantly increased in LVF [60]. The novel STIM2.1 variant is detected in both healthy and failing human myocardium. In severe LVF, STIM2.1 expression is significantly decreased. The lower ratio of STIM2.1/STIM2.2 ratio in failing hearts indicates a shift from the SOCE-inhibiting STIM2.1 variant to the stimulatory one, STIM2.2, suggesting an exacerbated SOCE in failing patients.

![Image](image_url)

**Figure 1.** Illustration of the changes in protein expression of the SOCE machinery in rodent left dysfunction models. n = number of articles.

At baseline, the cardiac specific deletion or overexpression of STIM1 in mice leads to a deterioration of the cardiac function with age [68,76–78], demonstrating that the basal level of STIM1 is critical for maintaining normal LV function. However, interestingly, STIM1 silencing appears to protect the animals subjected to pressure overload against the associated hypertrophic development. Indeed, in vivo STIM1 silencing by Ad-shRNA decreases STIM1-dependent \( l_{SOC} \) and protects the heart from pressure overload-induced hypertrophy by reducing signaling pathway activation such as Calcineurin (CaN)/NFATc3 [69]. After induction of compensated hypertrophy in mice by AAB for 4 weeks, in addition to STIM1 and Orai1 upregulation, a decrease in the SARAF (SOCE-associated regulatory factor) protein expression has also been reported, which inhibits STIM1-Orai1 interaction, whereas SARAF overexpression prevents STIM1 and Orai1 upregulation and attenuates hypertrophic development [79]. Stim1-KO mice, after 5 weeks of TAC, exhibit preserved left ventricular mass and cardiac function associated with normal extracellular signal-regulated kinase 1 and 2 (ERK1/2) activity and CaN expression [77]. STIM1 silencing via AAV9 before induction of pressure overload by TAC in mice promotes the transition from adaptive hypertrophy to maladaptive hypertrophy with a dilated failing heart and the presence of significant pulmonary edema [76]. When STIM1 extinction occurs 3 weeks after the establishment of pressure overload-induced cardiac hypertrophy, mice also exhibit marked ventricular dilatation associated with systolic dysfunction compared to WT mice, reflecting a more
rapid transition to HF. STIM1 would, therefore, be a key element in the development and
the persistence of compensated cardiac hypertrophy to preserve the transition to HF. The
chronic treatment with the cholinesterase inhibitor, pyridostigmine, after AAB or TAC in
rats or mice, respectively, attenuates cardiac hypertrophy and improves cardiac contractile
performance and rhythmic activity by suppressing the interaction of Orai1/STIM1 [80]
or diminishing pathologically enhanced STIM1 expression and SOCE in hypertrophied
myocytes [71].

Finally, the cardiac STIM1 overexpressing mice subjected to pressure overload by
TAC or to chronic neurohormonal stimulation by infusion of AngII/Phenylephrine (PE) or
isoproterenol for 2 weeks demonstrated severe maladaptive hypertrophy, with a decrease
in systolic function and the appearance of pulmonary edema, demonstrating a deleterious
effect of STIM1 overexpression on cardiac function under chronic stress [61].

With regard to the various in vivo experimental models of cardiac hypertrophy, there
are differences as to whether or not STIM1 expression is increased. Regardless, altering
STIM1-dependent signaling in vivo is deleterious for cardiac function, supporting the
idea that preserving STIM1 expression and activity under physiological and pathological
conditions is instrumental. On the other hand, most of the studies have investigated the
role of STIM1 in the pathogenesis of compensated hypertrophy. It would be interesting to
explore its role at more severe stages, where systolic dysfunction is established.

5.2. Role of Orai Channels

In line with the previous observations, mRNA and protein levels of Orai1 are found to
be upregulated in mouse LV hypertrophy induced by pressure and volume overloads, such
as 4 days or 5 weeks after TAC, 4 weeks after AAB, 2 weeks after AngII infusion, 4 days
post-myocardial infarction, or after ischemia-reperfusion injury [64,72,79,81–83] (Table 1
and Figure 1). An increased expression of Orai3 is also found after compensated or decomp-
ensated hypertrophy in mice and cats [72,74,81]. In the end-stage human LVF tissue, Orai1
expression is decreased by 30% only in males. Orai1 expression is unchanged in females
with LVF, suggesting the possible cardioprotective effects of estrogen by maintaining stable
Orai1 expression [62]. In contrast, enhanced Orai1 expression and increased SOCE are
found in fibroblasts from end-stage human LVF patients, associated with an enhanced
collagen secretion capacity [84]. No changes are detected for Orai2 and Orai3 in humans
(Table 1).

Interestingly, the effect of Orai1 invalidation at baseline varies between species. In
zebrafish, Orai1 deficient embryos spontaneously develop severe HF and bradycardia [64].
Similarly, heart-specific suppression of Orai1 in larvae and adult drosophila resulted in
reduced contractility that is consistent with dilated cardiomyopathy [84]. However, Orai1-
deficient or nonfunctional Orai1 mice have normal cardiac function, unlike those with a
STIM1 deficiency [72,73,81]. Later, in drosophila, it was found that heart-specific genetic
upregulation of constitutive active STIM1 and Orai1 proteins in larvae and adults resulted
in significant hypertrophy [85].

The Orai1-deficient mice (orai1+/−) subjected to pressure overload (TAC) for 8 weeks
have decreased survival, with faster cardiac functional loss and more significant ventricular
dilation when compared to WT mice [73]. This suggests that the loss of Orai1 accelerates
the pathology and results in the more rapid development of dilated cardiomyopathy and
HF. Cardiac hypertrophy level is similar between groups. However, orai1+/− mice are no
longer able to compensate for the overload, leading to the development of more severe
systolic dysfunction. This can be explained by significant apoptosis without differences in
hypertrophic and fibrotic markers.

In a model of HF with preserved ejection fraction by AngII infusion for 2 weeks in
mice, the cardiomyocyte-specific and temporally inducible Orai1 knockout mouse line
(Orai1CM-KO) show a slight decrease in systolic function with increased fibrosis compared
to WT mice, suggesting a worsening of the pathology and a transition towards maladaptive
hypertrophy. However, given the experimental echocardiographic data, these conclu-
sions seem hasty [81]. In contrast, we recently demonstrated that, after chronic pressure overload (5 weeks post-TAC), cardiomyocyte-specific dominant negative (dn)Orai1 R91W (loss of function Orai1 mutation) or in vivo pharmacological selective inhibition of Orai1 protects mice against LV systolic dysfunction and fibrosis, without a change in LV hypertrophy. The protection against LV dysfunction is associated with a normalization of SOCE, [Ca\(^{2+}\)] transients amplitude, SR Ca\(^{2+}\) load, cardiomyocyte contractility, and sarco/endoplasmic reticulum Ca\(^{2+}\)-ATPase (SERCA2a) expression, in which the protein tyrosine kinase (Pyk2)/mitogen-activated protein kinase (MEK)/ERK cascade is, in part, involved [72].

Saliba et al. showed the involvement of the Orai3 isoform during compensated cardiac hypertrophy induced by pressure overload in rats (4 weeks after AAB) [63]. In hypertrophied rats, the authors observed an increase in the interaction of Orai3 with STIM1/Orai1, leading to an increased rate of Orai3-mediated Ca\(^{2+}\) entry. This voltage-independent Ca\(^{2+}\) entry is not involved in the cardiac ECC, since the amplitude and the relaxation constant of the Ca\(^{2+}\) transients are not modified in hypertrophied rats in the presence of siRNAs directed against Orai3 or Orai1. Moreover, during pathology, arachidonic acid current (I\(_{ARC}\)) mediated by Orai3 is increased [63]. However, the authors did not address the functional significance of this enhanced Orai3-mediated Ca\(^{2+}\) entry in the pathological states [63]. Using constitutive and inducible cardiomyocyte-specific Orai3 knockout (KO) (Orai3\(^{cKO}\)) mice, Gammons et al. found that cardiac Orai3 deficiency lead to LV dysfunction progressing to dilated cardiomyopathy and LVF. Cardiomyocytes isolated from Orai3\(^{cKO}\) mice exhibit profoundly altered myocardial Ca\(^{2+}\) cycling and mitochondrial morphology. A more dramatic cardiac phenotype emerged when Orai3 is removed in adult mice using a tamoxifen-inducible Orai3\(^{cKO}\) mouse, indicating that the loss of cardiac Orai3 is critical for LV function. In a pathological state, Orai3\(^{cKO}\) mice subjected to pressure overload (2 weeks post-TAC) developed a fulminant dilated cardiomyopathy with rapid HF, characterized by interstitial fibrosis and apoptosis [86]. This has also been confirmed in vivo in two models of adaptive hypertrophy by infusion of isoproterenol for 15 days or by AAB for 28 days in rats. By intramyocardial injection of siRNA directed against Orai3, a rapid transition to maladaptive hypertrophy is demonstrated, showing a deleterious effect of knockdown Orai3 during adaptive hypertrophy [87].

In contrast to Orai3, the studies carried out in vivo on the role of Orai1 in hypertrophy and HF remains, to date, quite contradictory, probably due to the different experimental pathological models. Despite these discrepancies, all studies support the idea of a significant role of Orai1-mediated SOCE in the development of hypertrophy and HF.

5.3. Role of TRPC Channels

Under physiological conditions, all TRPCs-deficient mice presented no cardiac abnormality compared with WT mice [82], indicating that TRPC channels are not crucial for maintaining normal LV function. However, evidence suggested that TRPC channels contribute to the pathogenesis of LV hypertrophy or failure.

Almost all TRPC isoforms are differentially expressed in left ventricular tissue and cells isolated from experimental animal models of LV remodeling and dysfunction, and in myocardial biopsies from failing human hearts (Table 1 and Figure 1). Indeed, in different in vivo experimental rodent models of hypertrophy and HF induced by pressure or volume overload (abdominal, ascending or transverse aortic constriction, Dahl salt-sensitive, spontaneously hypertensive (SHR), myocardial infarction, ischemia-reperfusion injury) or by neurohormonal stress (PE, Endothelin-1 (ET-1), AngII, Isoproterenol), an increased expression of TRPC1 [54,57,59,65,82,88–92], TRPC2 [90], TRPC3 [59,90,93–96], TRPC4 [59,81,97], TRPC5 [83] and TRPC6 [59,72,81,90,94–96,98–104] has been reported. Additionally, increased expression of TRPC1 and TRPC5 expression in failing human hearts [93,105,106], increased TRPC6 mRNA in human LV with dilated cardiomyopathy [100], and decreased expression of TRPC4 in isolated LV myocytes from patients with ischemic cardiomyopathy and severe HF have been shown [105,107] (Table 1).
Table 1. SOCE Molecules Expression after Hypertrophic Stresses of the Left Ventricle. ↑: increase; ↔: no change; ↓ decrease; ND: not determined.

| SOCE Molecules | Expression Level | SOCE Function | Species | Induction of the LV Remodeling | References |
|----------------|------------------|---------------|---------|-------------------------------|------------|
| STIM1L         | ↑ (mRNA/Protein) | ↑ SOCE        | Mouse   | Thoracic aortic banding (3 weeks) | [46]       |
| STIM1          | ↔ (Protein)      |               | Mouse   | Thoracic aortic banding (3 weeks) /Calcineurin Tg mouse |           |
| STIM2          | ↔ (mRNA)         |               | Mouse   | Dilated cardiomyopathy        | [100]      |
| TRPC6          | ↑ (mRNA)         | ND            | Human   | Isoproterenol (4 mg/kg/day, 4 days) |           |
| TRPC1, TRPC3, TRPC4 | ↔ (mRNA)     |               | Mouse   | Spontaneous hypertensive heart failure (SHHR, 19 months) |           |
| TRPC3          | ↑ (Protein)      | ND            | Rat     | Thoracic aortic banding (7 days) | [93]       |
| TRPC5          | ↑ (mRNA/Protein) |               | Mouse   | Calcineurin Tg mouse (2 months) |           |
| TRPC1, TRPC4, TRPC6 | ↔ (mRNA/Protein) |               | Human   | Idiopathic dilated cardiomyopathy |           |
| STIM1          | ↑ (mRNA)         |               | Human   | Severe LV heart failure (NYHA III-IV class) | [60]       |
| Orai1          | ↔ (mRNA in female) ↓ (mRNA in male) |           | Human   | Ischemic cardiomyopathy       | [107]      |
| STIM2, Orai2, Orai3 | ↔ (mRNA) |               | Human   | Hypertrophic cardiomyopathy, Heart failure | [106]      |
| TRPC4          | ↓ (mRNA)         | ND            | Human   | End-stage heart failure (NYHA III-IV class) | [105]      |
| TRPC1          | ↑ (mRNA)         | ND            | Human   | Ischemia (45 min)/Reperfusion (1 week) injury | [83]       |
| TRPC1, TRPC3, TRPC5 | ↑ (mRNA)        |               | Mouse   | Ischemia (30 min)/Reperfusion (24 h) injury | [82]       |
| TRPC3, TRPC6   | ↔ (mRNA)         |               | Mouse   | Abdominal aortic banding (4 weeks) | [79]       |
| TRPC4          | ↓ (mRNA)         | ↑ SOCE        | Rat     | Abdominal aortic banding (4 weeks) | [57]       |
| Orai1, TRPC5   | ↑ (mRNA/Protein) |               | Mouse   | Abdominal aortic banding (4 weeks) | [92]       |
| STIM1, Orai1, TRPC1 | ↑ (mRNA/Protein) |               | Mouse   | Abdominal aortic banding (4 weeks) | [81]       |
| STIM1, Orai1   | ↑ (mRNA/Protein) |               | Mouse   | Abdominal aortic banding (4 weeks) | [80]       |
| TRPC1          | ↑ (mRNA/Protein) |               | Rat     | Abdominal aortic banding (4 weeks) | [92]       |
| STIM1          | ↔ (mRNA/Protein) |               | Rat     | Abdominal aortic banding (4 weeks) | [92]       |
| TRPC5, TRPC6   | ↔ (Protein)      |               | Rat     | Abdominal aortic banding (4 weeks) | [92]       |
| TRPC1          | ↑ (mRNA/Protein) |               | Rat     | Abdominal aortic banding (4 weeks) | [92]       |
| TRPC3, TRPC5, TRPC6 | ↔ (mRNA/Protein) |               | Rat     | Abdominal aortic banding (4 weeks) | [92]       |
| SOCE Molecules | Expression Level | SOCE Function | Species | Induction of the LV Remodeling | References |
|----------------|------------------|---------------|---------|-------------------------------|------------|
| STIM1          | ↑ (Protein)      | ↑ \(I_{SOC}\) and \(I_{CRAC}\) | Rat     | Abdominal aortic banding (14 days and 28 days) | [69]       |
| STIM1          | ↑ (mRNA/Protein) | ND            | Cat     | Ascending aorta banding (4 months) | [74]       |
| Orai3          | ↑ (mRNA)         | ND            | Mouse   | Ascending aortic banding (6 weeks) | [103]      |
| Orai1, STIM2   | ↔ (mRNA/Protein) | ND            | Mouse   | Transverse aortic banding (4 days) Myocardial infarction (4 days) | [64]       |
| TRPC6          | ↑ (Protein)      | ND            | Mouse   | Transverse aortic banding (2 weeks) | [61]       |
| TRPC1          | ↔ (Protein)      | ND            | Mouse   | Transverse aortic banding (4 weeks) | [63]       |
| Orai1          | ↑ (mRNA/Protein) | ND            | Mouse   | Transverse aortic banding (5 weeks) | [72]       |
| STIM1, Orai1, Orai3 | ↑ interaction between Orai3 and STIM1/Orai1 (Protein) | ↑ Orai3-mediated \(Ca^{2+}\) entry and ↑ \(I_{ARC}\) | Rat | Transverse aortic banding (4 weeks) | [63]       |
| TRPC3, TRPC6   | ↑ (mRNA)         | ND            | Mouse   | Transverse aortic banding (7 days) | [94]       |
| TRPC1          | ↔ (mRNA)         | ND            | Mouse   | Transverse aortic banding (8 weeks) | [104]      |
| TRPC6          | ↑ (mRNA)         | ND            | Mouse   | Transverse aortic banding (4 weeks) | [65]       |
| TRPC1          | ↑ (Protein)      | ND            | Mouse   | Transverse aortic banding (5 weeks) | [72]       |
| Orai1, Orai3, TRPC6, STIM2 | ↑ (mRNA/Protein) | ↑ SOCE | Mouse   | Transverse aortic banding (5 weeks) | [72]       |
| TRPC1, TRPC3, TRPC4, TRPC5, STIM1, Orai2 | ↔ (mRNA/Protein) | ↑ \(I_{SOC}\) | Mouse | Transverse aortic banding (4, 8 weeks) | [54]       |
| TRPC1          | ↑ (Protein)      | ↑ \(I_{SOC}\) | Mouse   | Transverse aortic banding (28 days) | [71]       |
| TRPC4α, TRPC4β | ↑ (Protein)      | ND            | Mouse   | Transverse aortic banding (8 weeks) | [97]       |
| Orai1, Orai2, Orai3, STIM1, TRPC4, TRPC6 | ↑ (mRNA) | ND | Mouse | Angiotensin II infusion (3 mg/kg/day, 2 weeks) | [81]       |
| TRPC1, TRPC3, STIM2 | ↔ (mRNA) | ND | Mouse | Angiotensin II infusion (400 ng/kg/min, 4 weeks) | [75]       |
| STIM1          | ↑ (mRNA/Protein) | ND            | Mouse   | Angiotensin II infusion (400 ng/kg/min, 4 weeks) | [75]       |
| SOCE Molecules       | Expression Level | SOCE Function | Species         | Induction of the LV Remodeling                              | References |
|----------------------|------------------|---------------|-----------------|-------------------------------------------------------------|------------|
| TRPC1, TRPC3, TRPC4, TRPC6 | ↑ (mRNA)         | ↑ SOCE        | Mouse           | Myocardial infarction (1, 2, 6 weeks)                       | [59]       |
| TRPC2, TRPC5         | ↔ (mRNA)         |               |                 |                                                             |            |
| TRPC6                | ↑ (mRNA/Protein) | ND            | Rat             | Myocardial infarction (1 month)                             | [95]       |
| TRPC3, TRPC6         | ↑ (Protein)      | ND            | Rat             | Myocardial infarction (1, 6, 24 h)                         | [96]       |
| TRPC1                | ↑ (Protein)      | ↑ Streh-activated Ca\textsuperscript{2+} entry | Rat             | Isoproterenol (5 mg/kg/5 days, 5 weeks)                     | [88]       |
| TRPC3, TRPC6         | ↔ (Protein)      | ↑ I\textsubscript{SOC} | Mouse          | Isoproterenol (2 mg/kg/day, 10 days)                       | [101]      |
| TRPC6                | ↑ (mRNA)         | ↑ I\textsubscript{SOC} |                 |                                                             |            |
| TRPC1                | ↑ (mRNA/Protein) | ND            | Rat             | Spontaneously hypertensive rat (SHR)                       | [89]       |
| TRPC6                | ↔ (mRNA)         | ND            | Rat             | Spontaneously hypertensive rat (SHR)                       | [102]      |
| TRPC1                | ↑ (Protein)      | ↑ Streh-activated Ca\textsuperscript{2+} entry | Mouse          | mdx with dilated cardiomyopathy (9–12 months)              | [91]       |
| TRPC1, TRPC6         | ↑ (mRNA/Protein) |               |                 |                                                             |            |
| TRPC2                | ↑ (mRNA)         |               | Mouse           | Tg dn-NRSF (neuron-restrictive silencer factor, 12–16 weeks) | [90]       |
| TRPC3                | ↓ (mRNA), ↑ (Protein) |               |                 |                                                             |            |
This TRPCs upregulation leads to exacerbated and cumulative SOCE and/or receptor-operated Ca\(^{2+}\) entry (ROCE) that activate signaling pathways, such as CaN/NFAT [43,44,89,94,101,103,108,109] and/or Calmoduline Kinase II [59,110], but also the NF-kB pathway [106], cascades involved in the process of hypertrophic remodeling, in particular, in the re-expression of fetal genes (MYH7, ACTA) and the induction of pro-hypertrophic genes (NPPA, NPPB, MEF2a, etc.).

The use of KO mouse models or models harboring dominant-negative TRPC channels mutations and pharmacological tools has confirmed their importance in hypertrophic development. Indeed, KO mice for \textit{trpc1} [54,92], double \textit{trpc1/trpc4} KOs [111,112], \textit{trpc3} KO [113–115], \textit{trpc6} KO [116], double \textit{trpc3/trpc6} KOs [117], dn-TRPC3, dn-TRPC4 and dn-TRPC6 [43,54,111] are protected from adaptive and maladaptive hypertrophy induced by mechanical stress or neurohormonal stimulation by decreasing the activity of the CaN/NFAT pathway [43,111,118], and/or interstitial fibrosis [43,111,113], or the expression of the Cav1.2 [115] or by alleviating cardiac mitochondrial dysfunction [114]. These findings highlight the cardio-protective effect of TRPCs’ downregulation against cardiac hypertrophy and failure.

On the other hand, the specific TRPC3 inhibitor, Pyr3, attenuates the adaptive hypertrophy induced by pressure overload in mice, once again supporting the significant role of TRPC3 in cardiac hypertrophy [119]. The combined pharmacological inhibition of TRPC3 and TRPC6 by selective antagonists GSK2332255B and GSK2833503A in vitro and in vivo is also cardioprotective, but with a limited effect in vivo [117]. Finally, selective in vivo inhibition of TRPC6 by BI749327 also improves cardiac function and prevents fibrosis deposition in mice subjected to pressure overload [104]. All the studies mentioned above show the significant role of TRPC channels in the development and progression of hypertrophy and HF. TRPCs-mediated SOCE/ROCE inhibition appears to be beneficial during the pathology. However, an individual modulation of the TRPC channels’ activity does not exist and is still challenging to achieve, because of the complexity of the TRPCs hetero-tetramerization.

5.4. The SOCE in the Adverse RV Remodeling

Contrary to the LV, the SOCE machinery expression in the RV is not yet studied and the physiological role of TRPC/Orai1/STIM1 proteins in adult RV cardiomyocytes is poorly investigated. In the RV, only a few pioneer studies demonstrated the contribution of SOCs in RV remodeling and dysfunction. Benoist et al. showed that \textit{Trpc1} mRNA expression is decreased and \textit{Trpc6} mRNA expression is increased in RVF induced by monocrotaline (MCT) exposure in rats (Table 2). This dysregulation could contribute to arrhythmias in this experimental model [120]. In maladaptive RV hypertrophy, induced by MCT exposure in rats, we found an increased expression of the glycosylated form of Orai1, as well as upregulation of TRPC1/TRPC4 expression and of the long STIM1 (STIM1L), associated with a decrease in the classic STIM1 protein in hypertrophied RV cardiomyocytes. This is correlated with an increased \(I_{\text{SOC}}\) current that is responsible for higher SR Ca\(^{2+}\) content and Ca\(^{2+}\) cycling, suggesting their contribution to the RV remodeling during hypertrophic stress [121].

\[
\begin{array}{|c|c|c|c|c|}
\hline
\textbf{SOCE Molecules} & \textbf{Expression Level} & \textbf{SOCE Function} & \textbf{Species} & \textbf{Induction of the RV Remodeling} & \textbf{References} \\
\hline
\textit{TRPC1} & \downarrow (mRNA) & ND & Rat & Monocrotaline (60–80 mg/kg, 3–5 weeks) & [120] \\
\textit{TRPC6} & \uparrow (mRNA) & ND & Rat & Monocrotaline (60 mg/kg, 3 weeks) & [121] \\
\textit{TRPC1}, \textit{TRPC4}, \textit{glycosylated Orai1}, \textit{STIM1L} & \uparrow (Protein) & \uparrow I_{\text{SOC}} & Rat & Monocrotaline (60 mg/kg, 3 weeks) & [121] \\
\textit{STIM2}, \textit{Orai3}, \textit{TRPC3}, \textit{TRPC6} & \leftrightarrow (Protein) & & & & \\
\textit{TRPC5}, \textit{STIM1} & \downarrow (Protein) & & & & \\
\hline
\end{array}
\]

\textbf{Table 2.} SOCE molecules expression after hypertrophic stresses of the Right Ventricle. \^: increase; \leftrightarrow: no change \downarrow decrease; ND: not determined.
5.5. Available Pharmacological Tools to Target SOCE in Heart Failure

Since the identification of Orai1 as the SOCs archetype, Orai1 is identified as a key player in several pathological contexts. That is why the arsenal of pharmacological Orai1 inhibitors has significantly increased over the last decade. Indeed, there is a well-described family of pyrazole derivatives, with the commonly used BTP2 (N-[4-[3,5-bis(Trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-4-methyl-1,2,3-thiadiazole-5-carboxamide or YM-58483) [122–125] and GSK compounds (GSK7975A and GSK-5503A) [126], the BTP2-derivative Synta-66, which binds directly Orai1 [127–129] and its suitable in vivo and more selective analog JPIII that we have developed [72,130]. The less-used AnCoA4 [131] and 5J4 (N-[(6-Hydroxy-1-naphthalenyl)amino]thioxomethyl]-2-furancarboxamide) [132] also exist. All these compounds have never been tested in humans. However, some Orai1 blockers (RP318, PRCL02, CM2489, Auxora) have already been tested in clinical trials (phase I/IIa) for severe plaque psoriasis, acute or chronic pancreatitis, and COVID-19 pneumonia [133–136], where all are well tolerated in patients [136].

We have demonstrated that Orai1 function contributes to human pulmonary arterial hypertension (PAH) and to several preclinical models of pulmonary hypertension (PH). We have showed that Orai1 inhibition, by BTP2, 5J4, or JPIII, corrects in vitro the aberrant phenotypes of human pulmonary artery smooth muscles cells and attenuates in vivo PH in rat models, suggesting that Orai1 inhibition should be considered a relevant therapy in PAH [130]. We have also demonstrated that, after chronic pressure overload, JPIII markedly improves the left ventricular systolic function and Ca\(^{2+}\) handling by preventing the Ca\(^{2+}\) cycling mishandling, SERCA2a downregulation and fibrosis, without causing adverse effect. Our findings suggest that Orai1 inhibition has a potential favorable hemodynamic value to protect the heart from maladaptive hypertrophy and might represent a new inotropic support to help to relieve systolic dysfunction [72]. Taken together, Orai1-mediated SOCE may be a novel therapeutic target to consider in PAH and HF. It would be interesting to test the Orai1 inhibitors used in clinical trials in PAH and HF, especially since good safety in humans has already been demonstrated in several clinical trials.

Contrary to Orai1 blockers, existing TRPC channel inhibitors are not selective of all TRPC channel isoforms. For example, the xanthine-based inhibitors inhibit TRPC1, TRPC5, and TRPC6 at nanomolar concentrations [137,138]. The HC-608 compound, also called Pico145, is described as one of the most potent inhibitors of TRPC1, TRPC4, and TRPC5 [139], while HC-070 is described as an inhibitor of TRPC4 and TRPC5 [140]. The ML-204 (4-Methyl-2-(1-piperidinyl)quinoline) compound is reported as a selective TRPC4 inhibitor [138], and AC1903 (C19H17N3O) as a selective TRPC5 inhibitor [141], but they are also described to inhibit TRPC4 and TRPC5. Alternatively, GB8438, a derivate of pyridazine 1 (Pyr1), is a potent TRPC4 and TRPC4/C5 inhibitor [142,143], while Pyr3 and Pyr10 are recognized as TRPC3 inhibitors [119]. The GSK2833503 compound is also a potent inhibitor of TRPC3 and TRPC6 [117,144]. Several compounds, including BI749327, SAR7334 SH045, and AM-1473, are developed to specifically inhibit TRPC6 [104,144–146]. Finally, the TRPC5 channel inhibitor, GFB887, is currently the only molecule tested in clinical Phase I on healthy volunteers and now in Phase II for patients with diabetic nephropathy or with focal segmental glomerulosclerosis [147].

Some of them can discriminate each TRPC isoform in vitro by using specific concentrations, but their use in vivo is challenging, due to their lack of selectivity at higher concentrations. Moreover, some compounds are not stable in vivo, which prevents their use in preclinical or clinical research. The development of selective TRPC channel inhibitors is needed and should be accelerated by recent cryo-EM structure discovery [148,149]. Developing more selective pharmacological tools to selectively inhibit each TRPC isoform could facilitate the emergence of innovative therapies for multiple diseases, such as LVF and RVF.
6. Conclusions and Future Directions

RVF is the most common cause of death in patients with PH, as the RV rapidly switches from adaptive to maladaptive hypertrophy in contrast to the LV. Although stopping or slowing down the progression of the RV disease appears necessary to avoid double transplantation, no treatment explicitly addresses RV dysfunction. As summarized in this review, SOCs are crucial for Ca\(^{2+}\) mishandling in LV dysfunction and could also be involved in RV dysfunction. Nevertheless, few studies have investigated the role of SOCs in the development of RV dysfunction. Additionally, the existing studies were performed in small animal models of RV dysfunction caused by pulmonary vessel remodeling. Further basic research studies are needed to decrypt the contribution of SOCE in RV remodeling in a large animal model or pulmonary arterial banding animals, and to investigate SOCs as novel potential therapeutic options during RV dysfunction.

Author Contributions: Conceptualization, J.S. and F.A.; writing—original draft preparation, J.S., A.B., R.L., B.M. and F.A; writing—review and editing, J.S., D.M., J.-P.B. and F.A; supervision, J.S. and F.A. funding acquisition, J.S., D.M., J.-P.B. and F.A. All authors have read and agreed to the published version of the manuscript.

Funding: This study was supported by grants from the French National Institute for Health and Medical Research (INSERM), the Université Paris-Saclay, the Marie Lannelongue Hospital. Fabrice Antigny received funding from the National Funding Agency for Research: ANR-18-CE14-0023 and funding from the French association “Fédération Française de Cardiologie”). Jean-Pierre Benitah received funding from the ANR: ANR-19-CE14-0031-1. RL was a recipient of the CSC (Chinese Scholarship Council) doctoral fellowship. Antoine Beauvais is supported by the French association “Fondation du Souffle”. Bastien Masson is supported by the Therapeutic Innovation Doctoral School (ED569).

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Conflicts of Interest: DM have relationships with drug companies, including Actelion, Bayer, GSK, Novartis, and Pfizer. In addition to being investigators in trials involving these companies, other relationships include consultancy services and memberships to scientific advisory boards. The other authors have no conflicts of interest to declare.

References
1. Vonk Noordegraaf, A.; Chin, K.M.; Haddad, F.; Hassoun, P.M.; Hemnes, A.R.; Hopkins, S.R.; Kawut, S.M.; Langleben, D.; Lumens, J.; Naeije, R. Pathophysiology of the Right Ventricle and of the Pulmonary Circulation in Pulmonary Hypertension: An Update. *Eur. Respir. J.* 2019, 53, 1801900. [CrossRef]
2. Haddad, F.; Hunt, S.A.; Rosenthal, D.N.; Murphy, D.J. Right Ventricular Function in Cardiovascular Disease, Part I: Anatomy, Physiology, Aging, and Functional Assessment of the Right Ventricle. *Circulation* 2008, 117, 1436–1448. [CrossRef] [PubMed]
3. Bogaard, H.J.; Abe, K.; Vonk Noordegraaf, A.; Voelkel, N.F. The Right Ventricle under Pressure: Cellular and Molecular Mechanisms of Right-Heart Failure in Pulmonary Hypertension. *Chest* 2009, 135, 794–804. [CrossRef] [PubMed]
4. Harjola, V.-P.; Mebazaa, A.; Čelutkienė, J.; Bettx, D.; Bueno, H.; Chioncel, O.; Crespo-Leiro, M.G.; Falk, V.; Filippatos, G.; Gibbs, S.; et al. Contemporary Management of Acute Right Ventricular Failure: A Statement from the Heart Failure Association and the Working Group on Pulmonary Circulation and Right Ventricular Function of the European Society of Cardiology. *Eur. J. Heart Fail.* 2016, 18, 226–241. [CrossRef] [PubMed]
5. Konstantinides, S.V.; Meyer, G.; Becattini, C.; Bueno, H.; Geersing, G.-J.; Harjola, V.-P.; Huisman, M.V.; Humbert, M.; Jennings, C.S.; Jiménez, D.; et al. 2019 ESC Guidelines for the Diagnosis and Management of Acute Pulmonary Embolism Developed in Collaboration with the European Respiratory Society (ERS): The Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). *Eur. Respir. J.* 2019, 54, 1901647. [CrossRef]
6. Ponikowski, P.; Voors, A.A.; Anker, S.D.; Bueno, H.; Cleland, J.G.F.; Coats, A.J.S.; Falk, V.; González-Juanatey, J.R.; Harjola, V.-P.; Jankowska, E.A.; et al. 2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology (ESC) Developed with the Special Contribution of the Heart Failure Association (HFA) of the ESC. *Eur. Heart J.* 2016, 37, 2129–2200. [CrossRef]
7. Raina, A.; Humbert, M. Risk Assessment in Pulmonary Arterial Hypertension. *Eur. Respir. Rev. Off. J. Eur. Respir. Soc.* 2016, 25, 390–398. [CrossRef]
Cells 2022, 11, 3282

8. Sanz, J.; Sánchez-Quintana, D.; Bossone, E.; Bogaard, H.J.; Naeije, R. Anatomy, Function, and Dysfunction of the Right Ventricle: JACC State-of-the-Art Review. *J. Am. Coll. Cardiol.* 2019, 73, 1463–1482. [CrossRef]
9. Dell’Italia, L.J. The Right Ventricle: Anatomy, Physiology, and Clinical Importance. *Curr. Probl. Cardiol.* 1991, 16, 653–720. [CrossRef]
10. Ashley, L.M. A Determination of the Diameters of Ventricular Myocardial Fibers in Man and Other Mammals. *Am. J. Anat.* 1945, 77, 325–363. [CrossRef]
11. Kelly, R.G.; Buckingham, M.E.; Moorman, A.F. Heart Fields and Cardiac Morphogenesis. *Cold Spring Harb. Perspect. Med.* 2014, 4, a015750. [CrossRef] [PubMed]
12. Kiserud, T.; Acharya, G. The Fetal Circulation. *Prenat. Diagn.* 2004, 24, 1049–1059. [CrossRef] [PubMed]
13. Waskovava-Arnstovo, P.; Elsnicova, B.; Kasparova, D.; Sebesta, O.; Novotny, J.; Neckar, J.; Kolar, F.; Zurnanovova, J. Right-to-Left Ventricular Differences in the Expression of Mitochondrial Hexokinase and Phosphorylation of Akt. *Cell. Physiol. Biochem.* Int. J. Exp. Cell Physiol. Biochem. Pharmacol. 2013, 31, 66–79. [CrossRef] [PubMed]
14. Antigny, F.; Mercier, O.; Humbert, M.; Sabourin, J. Excitation-Contraction Coupling and Relaxation Alteration in Right Ventricular Remodelling Caused by Pulmonary Arterial Hypertension. *Arch. Cardiov. Dis.* 2020, 113, 70–84. [CrossRef] [PubMed]
15. Benitah, J.P.; Gomez, A.M.; Virlsoly, A.; Richard, S. New Perspectives on the Key Role of Calcium in the Progression of Heart Disease. *J. Muscle Res. Cell Motil.* 2003, 24, 275–283. [CrossRef]
16. Putney, J.W. A Model for Receptor-Regulated Calcium Entry. *Cell Calcium* 1986, 7, 1–12. [CrossRef]
17. Wen, H.; Gwathmey, J.K.; Xie, L.-H. Role of Transient Receptor Potential Canonical Channels in Heart Physiology and Pathophysiology. *Front. Cardiov. Med.* 2020, 7, 24. [CrossRef]
18. Antigny, F.; Koenig, S.; Bernheim, L.; Frieden, M. During Post-Natal Human Myogenesis, Normal Myotube Size Requires TRPC1 and TRPC4-Mediated Ca2+ Entry. *J. Cell Sci.* 2013, 126, 2525–2533. [CrossRef]
19. Antigny, F.; Sabourin, J.; Saucé, S.; Bernheim, L.; Koenig, S.; Frieden, M. TRPC1 and TRPC4 Channels Functionally Interact with STIM1 to Promote Myogenesis and Maintain Fast Repetitive Ca2+(+)+ Release in Human Myotubes. *Biochim. Biophys. Acta* 2017, 1864, 806–813. [CrossRef]
20. Antigny, F.; Girardin, N.; Frieden, M. Transient Receptor Potential Canonical Channels Are Required for in Vitro Endothelial Tube Formation. *J. Biol. Chem.* 2012, 287, 9917–9927. [CrossRef]
21. Sabourin, J.; Le Gal, L.; Saurwein, L.; Haefliger, J.-A.; Raddatz, E.; Allagnat, F. Store-Operated Ca2+ Channels by STIM1 at ER-Plasma Membrane Junctions. *J. Cell Biol.* 2011, 194, 335–346. [CrossRef]
22. Ramesh, G.; Jarzembowski, L.; Schwarz, Y.; Poth, V.; Konrad, M.; Knapp, M.L.; Schwär, G.; Lauer, A.A.; Grimm, M.O.W.; Alansary, Á.; Dell'Italia, L.J. The Right Ventricle: Anatomy, Physiology, and Clinical Importance. *Handb. Exp. Pharmacol.* 2014, 223, 1035–1054. [CrossRef]
36. Zeng, W.; Yuan, J.P.; Kim, M.S.; Choi, Y.J.; Huang, G.N.; Worley, P.F.; Muallem, S. STIM1 Gates TRPC Channels, but Not Orai1, by Electrostatic Interaction. *Mol. Cell* 2008, 32, 439–448. [CrossRef]

37. Takemura, T.; Matsu, Y.; Sakit, S.; Mikami, R. Pulmonary Vascular Involvement in Sarcoidosis: A Report of 40 Autopsy Cases. *Hum. Pathol.* 1992, 23, 1216–1223. [CrossRef]

38. Hunton, D.L.; Lucchesi, P.A.; Pang, Y.; Cheng, X.; Dell’Italia, L.J.; Marchase, R.B. Capacitative Calcium Entry Contributes to Nuclear Factor of Activated T-Cells Nuclear Translocation and Hypertrophy in Cardiomyocytes. *J. Biol. Chem.* 2002, 277, 14266–14273. [CrossRef]

39. Uehara, A.; Yasukochi, M.; Imanaga, I.; Nishi, M.; Takeshima, H. Store-Operated Ca\(^{2+}\) Entry Uncoupled with Ryanode Receptor and Junctional Membrane Complex in Heart Muscle Cells. *Cell Calcium* 2002, 31, 89–96. [CrossRef]

40. Huang, J.; van Breemen, C.; Kuo, K.-H.; Hove-Madsen, L.; Tibbits, G.F. Store-Operated Ca\(^{2+}\) Entry Modulates Sarcoplasmic Reticulum Ca\(^{2+}\) Loading in Neonatal Rabbit Cardiac Ventricular Myocytes. *Am. J. Physiol. Cell Physiol.* 2006, 290, C1572–C1582. [CrossRef]

41. Kojima, A.; Kitagawa, H.; Omatu-Kanbe, M.; Matsuura, H.; Nosaka, S. Presence of Store-Operated Ca\(^{2+}\) Entry in CS7BL/6J Mouse Ventricular Myocytes and Its Suppression by Sevoflurane. *Br. J. Anaesth.* 2012, 109, 352–360. [CrossRef] [PubMed]

42. Wen, H.; Zhao, Z.; Feleflova, N.; Xie, L.-H. Potential Arrhythogenic Role of TRPC Channels and Store-Operated Calcium Entry Mechanism in Mouse Ventricular Myocytes. *Front. Physiol.* 2018, 9, 1785. [CrossRef] [PubMed]

43. Wu, X.; Eder, P.; Chang, B.; Molkentin, J.D. TRPC Channels Are Necessary Mediators of Pathologic Cardiac Hypertrophy. *Proc. Natl. Acad. Sci. USA* 2010, 107, 7000–7005. [CrossRef] [PubMed]

44. Gao, H.; Wang, F.; Wang, W.; Makarewich, C.A.; Zhang, H.; Kubo, H.; Berretta, R.M.; Barr, L.A.; Molkentin, J.D.; Houser, S.R. Ca\(^{2+}\) Influx through L-Type Ca\(^{2+}\) Channels and Transient Receptor Potential Channels Activates Pathological Hypertrophy Signaling. *J. Mol. Cell. Cardiol.* 2012, 53, 657–667. [CrossRef] [PubMed]

45. Touchberry, C.D.; Elmore, C.J.; Nguyen, T.M.; Andresen, J.J.; Zhao, X.; Orange, M.; Weisleder, N.; Brotto, M.; Claycomb, W.C.; Wacker, M.J. Store-Operated Calcium Entry Is Present in HL-1 Cardiomyocytes and Contributes to Resting Calcium. *Biochim. Biophys. Res. Commun.* 2011, 416, 45–50. [CrossRef]

46. Luo, X.; Hojayev, B.; Jiang, N.; Wang, Z.V.; Tandan, S.; Rakalin, A.; Rothermel, B.A.; Gillette, T.G.; Hill, J.A. STIM1-Dependent Store-Operated Ca\(^{2+}\) Entry Is Required for Pathological Cardiac Hypertrophy. *J. Mol. Cell. Cardiol.* 2012, 52, 136–147. [CrossRef]

47. Sabourin, J.; Bartoli, F.; Antigny, F.; Gomez, A.M.; Benitah, J.-P. Transient Receptor Potential Canonical (TRPC)/Orai1-Dependent Store-Operated Ca\(^{2+}\) Channels: NEW TARGETS OF ALDOSTERONE IN CARDIOMYOCYTES. *J. Biol. Chem.* 2016, 291, 13394–13409. [CrossRef]

48. Bartoli, F.; Sabourin, J. Cardiac Remodeling and Disease: Current Understanding of STIM1/Orai1-Mediated Store-Operated Ca\(^{2+}\) Entry in Cardiac Function and Pathology. *Adv. Exp. Med. Biol.* 2017, 993, 523–534. [CrossRef] [PubMed]

49. Bonilla, I.M.; Belevych, A.E.; Baine, S.; Stepanov, A.; Mezache, L.; Bodnar, T.; Liu, B.; Volpe, P.; Priori, S.; Weisleder, N.; et al. Enhancement of Cardiac Store Operated Calcium Entry (SOCE) within Novel Intercalated Disk Microdomains in Arrhythmic Disease. *Sci. Rep.* 2019, 9, 10179. [CrossRef]

50. Pan, Z.; Brotto, M.; Ma, J. Store-Operated Ca\(^{2+}\) Entry in Muscle Physiology and Diseases. *BMB Rep.* 2014, 47, 69–79. [CrossRef]

51. Dominguez-Rodriguez, A.; Ruiz-Hurtado, G.; Sabourin, J.; Gomez, A.M.; Alvarez, J.L.; Benitah, J.-F. Transient Receptor Potential Canonical (TRPC)/Orai1-Dependent Store-Operated Ca\(^{2+}\) Channels: Sustained Activation of ER Ca\(^{2+}\) Influx. *Adv. Exp. Med. Biol.* 2019, 993, 69–79. [CrossRef] [PubMed]

52. Bootman, M.D.; Rietdorf, K. Tissue Specificity: Store-Operated Ca\(^{2+}\) Entry in Cardiac Myocytes. *Adv. Exp. Med. Biol.* 2017, 993, 363–387. [CrossRef] [PubMed]

53. Sabourin, J.; Robin, E.; Raddatz, E. A Key Role of TRPC Channels in the Regulation of Electromechanical Activity of the Developing Heart. *Cardiovasc. Res.* 2011, 92, 226–236. [CrossRef]

54. Seth, M.; Zhang, Z.-S.; Mao, L.; Graham, V.; Burch, J.; Sibner, J.; Tsiokas, L.; Winn, M.; Abramowitz, J.; Rockman, H.A.; et al. TRPC1 Channels Are Critical for Hypertrophic Signaling in the Heart. *Circ. Res.* 2009, 105, 1023–1030. [CrossRef]

55. Watanabe, H.; Murakami, M.; Ohba, T.; Takahashi, Y.; Ito, H. TRP Channel and Cardiovascular Disease. *Pharmacol. Ther.* 2008, 118, 337–351. [CrossRef] [PubMed]

56. Watanabe, H.; Murakami, M.; Ohba, T.; Ono, K.; Ito, H. The Pathological Role of Transient Receptor Potential Channels in Heart Disease. *Circ. J.* 2009, 73, 419–427. [CrossRef]

57. Ohba, T.; Watanabe, H.; Murakami, M.; Sato, T.; Ono, K.; Ito, H. Essential Role of STIM1 in the Development of Cardiomyocyte Hypertrophy. *Biochem. Biophys. Res. Commun.* 2009, 389, 172–176. [CrossRef]

58. Sabourin, J.; Antigny, F.; Robin, E.; Frieden, M.; Raddatz, E. Activation of Transient Receptor Potential Canonical 3 (TRPC3)-Mediated Ca\(^{2+}\) Entry by A1 Adenosine Receptor in Cardiomyocytes Disturbs Atrophicventricular Conduction. *J. Biol. Chem.* 2012, 287, 26688–26701. [CrossRef]

59. Makarewich, C.A.; Zhang, H.; Davis, J.; Correll, R.N.; Trappanese, D.M.; Hoffman, N.E.; Troupes, C.D.; Berretta, R.M.; Kubo, H.; Madesh, M.; et al. Transient Receptor Potential Channels Contribute to Pathological Structural and Functional Remodeling after Myocardial Infarction. *Circ. Res.* 2014, 115, 567–580. [CrossRef]

60. Čendula, R.; Drágun, M.; Gázdová, A.; Kyselovič, J.; Hulman, M.; Mátiaš, M. Changes in STIM Isoforms Expression and Gender-Specific Alterations in Oral Expression in Human Heart Failure. *Physiol. Res.* 2019, 68, S165–S172. [CrossRef]
61. Correll, R.N.; Goonasekera, S.A.; van Berlo, J.H.; Burr, A.R.; Accornero, F.; Zhang, H.; Makarewich, C.A.; York, A.J.; Sargent, M.A.; Chen, X.; et al. STIM1 Elevation in the Heart Results in Aberrant Ca\(^{2+}\) Handling and Cardiomyopathy. *J. Mol. Cell. Cardiol.* 2015, 87, 38–47. [CrossRef] [PubMed]

62. Malette, J.; Degrandmaison, J.; Gigueré, H.; Berthiaume, J.; Frappier, M.; Parent, J.-L.; Auger-Messier, M.; Boulay, G. MURC/Cavin-4 Facilitates Store-Operated Calcium Entry in Neonatal Cardiomyocytes. *Biochim. Biophys. Acta Mol. Cell Res.* 2019, 1866, 1249–1259. [CrossRef] [PubMed]

63. Saliba, Y.; Keck, M.; Marchand, A.; Atassi, F.; Ouillé, A.; Cazorla, O.; Trebak, M.; Pavoine, C.; Lacampagne, A.; Hulot, J.-S.; et al. Emergence of Orai3 Activity during Cardiac Hypertrophy. *Cardiovasc. Res.* 2014, 105, 248–259. [CrossRef] [PubMed]

64. Völkers, M.; Dolatabadi, N.; Gude, N.; Most, P.; Sussman, M.A.; Hassel, D. Orai1 Deficiency Leads to Heart Failure and Skeletal Myopathy in Zebrafish. *J. Cell Sci.* 2012, 125, 287–294. [CrossRef]

65. Ohba, T.; Watanabe, H.; Murakami, M.; Iino, K.; Adachi, T.; Baba, Y.; Kurosaki, T.; Ono, K.; Ito, H. Stromal Interaction Molecule 1 Haploinsufficiency Causes Maladaptive Response to Pressure Overload. *PLoS ONE* 2017, 12, e0187950. [CrossRef]

66. Wolokowicz, P.E.; Huang, J.; Umeda, P.K.; Sharifov, O.F.; Tabengwa, E.; Halloran, B.A.; Urthaler, F.; Grennet, H.E. Pharmacological Evidence for Orai Channel Activation as a Source of Cardiac Abnormal Automaticity. *Eur. J. Pharmacol.* 2011, 668, 208–216. [CrossRef]

67. Vig, M.; Peinelt, C.; Beck, A.; Koomoa, D.L.; Rabah, D.; Koblan-Huberson, M.; Kraft, S.; Turner, H.; Fleig, A.; Penner, R.; et al. CRACM1 Is a Plasma Membrane Protein Essential for Store-Operated Ca\(^{2+}\) Entry. *Science* 2006, 312, 1220–1223. [CrossRef]

68. Collins, H.E.; He, L.; Zus, L.; Qu, J.; Zhou, L.; Litovsky, S.H.; Yang, Q.; Young, M.E.; Marchase, R.B.; Chatham, J.C. Stromal Interaction Molecule 1 Is Essential for Normal Cardiac Homeostasis through Modulation of ER and Mitochondrial Function. *Am. J. Physiol. Heart Circ. Physiol.* 2014, 306, H1231–H1239. [CrossRef] [PubMed]

69. Hulot, J.-S.; Fauconnier, J.; Ramanujam, D.; Chaanine, A.; Aubart, F.; Sassi, Y.; Merkle, S.; Cazorla, O.; Ouillé, A.; Dupuis, M.; et al. Critical Role for Stromal Interaction Molecule 1 in Cardiac Hypertrophy. *Circulation* 2011, 124, 796–805. [CrossRef]

70. Zhang, H.; Sun, A.Y.; Kim, J.J.; Graham, V.; Finch, E.A.; Nepliouev, I.; Zhao, G.; Li, T.; Lederer, W.J.; Sibler, J.A.; et al. STIM1-Ca\(^{2+}\) Signaling Modulates Automaticity of the Mouse Sinoatrial Node. *Proc. Natl. Acad. Sci. USA* 2015, 112, E5618–E5627. [CrossRef]

71. Baine, S.; Bonilla, I.; Belevych, A.; Stepanov, A.; Dorn, L.E.; Terentyeva, R.; Terentyev, D.; Accornero, F.; Carnes, C.A.; Gyorke, S. Pyridostigmine Improves Cardiac Function and Rhythm Stability through RyR2 Stabilization and Inhibition of STIM1-mediated Calcium Entry in Heart Failure. *J. Cell. Mol. Med.* 2021, 25, 4637–4648. [CrossRef]

72. Bartoli, F.; Bailey, M.A.; Rode, B.; Mateo, P.; Antigny, F.; Bedouet, K.; Gerbaud, P.; Gosain, R.; Plante, J.; Norman, K.; et al. Orai1 Channel Inhibition Preserves Left Ventricular Systolic Function and Normal Ca\(^{2+}\) Handling After Pressure Overload. *Circulation* 2020, 141, 199–216. [CrossRef] [PubMed]

73. Horton, J.S.; Buckley, C.L.; Alvarez, E.M.; Schorlemmer, A.; Stokes, A.J. The Calcium Release-Activated Calcium Channel Orai1 Represents a Crucial Component in Hypertrophic Compensation and the Development of Dilated Cardiomyopathy. *Channels* 2014, 8, 35–48. [CrossRef]

74. Troupes, C.D.; Wallner, M.; Borghetti, G.; Zhang, C.; Mohsin, S.; von Lewinski, D.; Berretta, R.M.; Kubo, H.; Chen, X.; Soboloff, J.; et al. Role of STIM1 in Hypertrophy-Related Contractile Dysfunction. *Circ. Res.* 2017, 121, 125–136. [CrossRef]

75. Kassan, M.; Ait-Aissa, K.; Radwani, E.; Mali, V.; Haddox, S.; Gabani, M.; Zhang, W.; Belmadani, S.; Irani, K.; Trebak, M.; et al. Essential Role of Smooth Muscle STIM1 in Hypertension and Cardiovascular Dysfunction. *Arterioscler. Thromb. Vasc. Biol.* 2016, 36, 1900–1905. [CrossRef] [PubMed]

76. Bénard, L.; Oh, J.G.; Cacheux, M.; Lee, A.; Nonnenmacher, M.; Matasic, D.S.; Kohlbrenner, E.; Kho, C.; Pavoine, C.; Hajjar, R.J.; et al. Cardiac Stim1 Silencing Impairs Adaptive Hypertrophy and Promotes Heart Failure Through Inactivation of MTORC2/Akt Signaling. *Circulation* 2016, 133, 1458–1471, discussion 1471. [CrossRef]

77. Parks, C.; Alam, M.A.; Sullivan, R.; Mancarella, S. STIM1-Dependent Ca\(^{2+}\) Microdomains Are Required for Myofilament Remodeling and Signaling in the Heart. *Sci. Rep.* 2016, 6, 25372. [CrossRef]

78. Cacheux, M.; Strauss, B.; Raad, N.; Ilkan, Z.; Hu, J.; Bénard, L.; Feske, S.; Hulot, J.-S.; Arai, F.G. Cardiomyocyte-Specific STIM1 (Stromal Interaction Molecule 1)Depletion in the Adult Heart Promotes the Development of Arhythmogenic Discordant Alternans. *Circ. Arrhythm. Electrophysiol.* 2019, 12, e007382. [CrossRef]

79. Dai, F.; Zhang, Y.; Wang, Q.; Li, D.; Yang, Y.; Ma, S.; Yang, D. Overexpression of SARAF Ameliorates Pressure Overload-Induced Cardiac Hypertrophy Through Suppressing STIM1-Orai1 in Mice. *Cell. Physiol. Biochem. Int. J. Exp. Cell. Physiol. Biochem. Pharmacol.* 2018, 47, 817–826. [CrossRef] [PubMed]

80. Lu, Y.; Zhao, M.; Liu, J.-J.; He, X.; Yu, X.-J.; Liu, L.-Z.; Sun, L.; Chen, L.-N.; Zang, W.-N. Long-Term Administration of Pyridostigmine Attenuates Pressure Overload-Induced Cardiac Hypertrophy by Inhibiting Calcineurin Signalling. *J. Cell. Mol. Med.* 2017, 21, 2106–2116. [CrossRef]

81. Segin, S.; Berlin, M.; Richter, C.; Flockerzi, R.M.V.; Worley, P.; Freichel, M.; Londoño, J.E.C. Cardiomyocyte-Specific Deletion of Orai1 Reveals Its Protective Role in Angiotsensin-II-Induced Pathological Cardiac Remodeling. *Cells* 2020, 9, 1092. [CrossRef] [PubMed]

82. He, F.; Wu, Q.; Xu, B.; Wang, X.; Wu, J.; Huang, L.; Cheng, J. Suppression of Stim1 Reduced Intracellular Calcium Concentration and Attenuated Hypoxia/Reoxygenation Induced Apoptosis in H9C2 Cells. *Biosci. Rep.* 2017, 37, BSR20171249. [CrossRef] [PubMed]
83. Dominguez-Rodriguez, A.; Mayoral-Gonzalez, I.; Avila-Medina, J.; de Rojas-de Pedro, E.S.; Calderón-Sánchez, E.; Díaz, I.; Hmadcha, A.; Castellano, A.; Rosado, J.A.; Benitah, J.-P.; et al. Urocortin-2 Prevents Disregulation of Ca²⁺ Homeostasis and Improves Early Cardiac Remodeling After Ischemia and Reperfusion. *Front. Physiol.* 2018, 9, 813. [CrossRef]

84. Ross, G.R.; Bajwa, T.; Edwards, S.; Emelyanova, L.; Rizvi, E.; Holmuhamedov, E.L.; Werner, P.; Downey, F.X.; Tajik, A.J.; Jahangir, A. Enhanced Store-Operated Ca²⁺ Influx and ORAI1 Expression in Ventricular Fibroblasts from Human Failing Heart. *Biol. Open* 2017, 6, 326–332. [CrossRef]

85. Petersen, C.E.; Tripoli, B.A.; Schoborg, T.A.; Smyth, J.T. Analysis of Drosophila Cardiac Hypertrophy by Microcomputerized Tomography for Genetic Dissection of Heart Developmental Mechanisms. *Am. J. Physiol. Heart Circ. Physiol.* 2022, 322, H296–H309. [CrossRef]

86. Gammons, J.; Trebak, M.; Mancarella, S. Cardiac-Specific Deletion of Orai3 Leads to Severe Dilated Cardiomyopathy and Heart Failure in Mice. *J. Am. Heart Assoc.* 2021, 10, e019486. [CrossRef]

87. Keck, M.; Flamant, M.; Mougnot, N.; Favier, S.; Atassi, F.; Barbier, C.; Nadaud, S.; Lompré, A.-M.; Hulot, J.-S.; Pavone, C. Cardiac Inflammatory CD11b/c Cells Exert a Protective Role in Hypertrophied Cardiomyocyte by Promoting TNFR2- and Orai3-Dependent Signaling. *Sci. Rep.* 2019, 9, 6047. [CrossRef] [PubMed]

88. Chen, M.-S.; Xiao, J.-H.; Wang, Y.; Xu, B.-M.; Gao, L.; Wang, J.-L. Upregulation of TRPC1 Contributes to Contractile Function in Isoproterenol-Induced Hypertrophic Myocardium of Rat. *Cell. Physiol. Biochem. Int. J. Exp. Cell. Physiol. Biochem. Pharmacol.* 2013, 32, 951–959. [CrossRef]

89. Zou, G.; Hong, H.; Lin, X.; Shi, X.; Wu, Y.; Chen, L. TRPC1, CaN and NFATC3 Signaling Pathway in the Pathogenesis and Progression of Left Ventricular Hypertrophy in Spontaneously Hypertensive Rats. *Clin. Exp. Hypertens.* 2015, 37, 223–234. [CrossRef]

90. Ohba, T.; Watanabe, H.; Takahashi, Y.; Suzuki, T.; Miyoshi, I.; Nakayama, S.; Satoh, E.; Iino, K.; Sasano, H.; Mori, Y.; et al. Regulatory Role of Neuron-Restrictive Silencing Factor in Expression of TRPC1. *Biochem. Biophys. Res. Commun.* 2006, 351, 764–770. [CrossRef]

91. Ward, M.-L.; Williams, I.A.; Chu, Y.; Cooper, P.J.; Ju, Y.-K.; Allen, D.G. Stretch-Activated Channels in the Heart: Contributions to Length-Dependence and to Cardiomyopathy. *Prog. Biophys. Mol. Biol.* 2008, 97, 232–249. [CrossRef]

92. Ohba, T.; Watanabe, H.; Murakami, M.; Takahashi, Y.; Iino, K.; Kuromitsu, S.; Mori, Y.; Ono, K.; Iijima, T.; Ito, H. Upregulation of TRPC1 in the Development of Cardiac Hypertrophy. *J. Mol. Cell. Cardiol.* 2007, 42, 498–507. [CrossRef] [PubMed]

93. Bush, E.W.; Hood, D.B.; Papst, P.J.; Chapo, J.A.; Minobe, W.; Bristow, M.R.; Olson, E.N.; McKinsey, T.A. Canonical Transient Receptor Potential Channels Promote Cardiomyocyte Hypertrophy through Activation of Calcineurin Signaling. *J. Biol. Chem.* 2006, 281, 33487–33496. [CrossRef]

94. Koitabashi, N.; Aiba, T.; Hesketh, G.G.; Rowell, J.; Zhang, M.; Takimoto, E.; Tomasselli, G.F.; Kass, D.A. Cyclic GMP/PKG-Dependent Inhibition of TRPC6 Channel Activity and Expression Negatively Regulates Cardiomyocyte NFAT Activation Novel Mechanism of Cardiac Stress Modulation by PDE5 Inhibition. *J. Mol. Cell. Cardiol.* 2010, 48, 713–724. [CrossRef]

95. Zhou, R.; Hang, P.; Zhu, W.; Su, Z.; Liang, H.; Du, Z. Whole Genome Network Analysis of Ion Channels and Connexins in Myocardial Infarction. *Cell. Physiol. Biochem. Int. J. Exp. Cell. Physiol. Biochem. Pharmacol.* 2011, 27, 299–304. [CrossRef]

96. Hang, P.; Zhao, J.; Cai, B.; Tian, S.; Huang, W.; Guo, J.; Sun, C.; Li, Y.; Du, Z. Brain-Derived Neurotrophic Factor Regulates TRPC3/6 Channels and Protects against Myocardial Infarction in Rodents. *Int. J. Biol. Sci.* 2015, 11, 536–545. [CrossRef]

97. Kirschner, N.; Bandleon, S.; von Ehrlich-Treuenstätt, V.; Hartmann, S.; Schaaf, A.; Pavoine, C. Regulatory Role of Neuron-Restrictive Silencing Factor in Expression of TRPC1. *Biochem. Biophys. Res. Commun.* 2020, e0168446. [CrossRef]

98. Onohara, N.; Nishida, M.; Inoue, R.; Kobayashi, H.; Sumimoto, H.; Sato, Y.; Mori, Y.; Nagao, T.; Kurose, H. TRPC3 and TRPC6 Are Essential for Angiotensin II-Induced Cardiac Hypertrophy. *EMBO J.* 2006, 25, 5305–5316. [CrossRef] [PubMed]

99. Brenner, J.S.; Dolketsch, R.E. TRP3 Regulates Hypertrophy-Associated Gene Expression without Affecting Myocyte Beating or Cell Size. *PLoS ONE* 2007, 2, e802. [CrossRef]

100. Kuwahara, K.; Wang, Y.; McNally, J.; Richardson, J.A.; Bassel-Duby, R.; Hill, J.A.; Olson, E.N. TRPC6 Fullfills a Calcineurin Signaling Circuit during Pathologic Cardiac Remodeling. *J. Clin. Investig.* 2006, 116, 3114–3126. [CrossRef]

101. Xie, J.; Cha, S.-K.; An, S.-W.; Kuro-o, M.; Birnbaumer, L.; Huang, C.-L. Cardioprotection by Klotho through Downregulation of TRPC6 Channels in the Mouse Heart. *Nat. Commun.* 2012, 3, 1238. [CrossRef] [PubMed]

102. Bogdanova, E.; Beresneva, O.; Galkina, O.; Zubina, I.; Ivanova, G.; Parastaeva, M.; Semenova, N.; Dobronravov, V. Myocardial Hypertrophy and Fibrosis Are Associated with Cardiomyocyte Beta-Catenin and TRPC6/Calcineurin/NFAT Signaling in Spontaneously Hypertensive Rats with 5/6 Nephrectomy. *Int. J. Mol. Sci.* 2021, 22, 4645. [CrossRef] [PubMed]

103. Vindis, C.; D’Angelo, R.; Mucher, E.; Negre-Salvayre, A.; Parini, A.; Miallet-Perez, J. Essential Role of TRPC1 Channels in Cardiomyoblasts Hypertrophy Mediated by 5-HT2A Serotonin Receptors. *Biochem. Biophys. Res. Commun.* 2010, 391, 979–983. [CrossRef] [PubMed]

104. Lin, B.L.; Matera, D.; Doerner, J.F.; Zheng, N.; del Camino, D.; Mishra, S.; Bian, H.; Zeveleva, S.; Zhen, X.; Blair, N.T.; et al. In Vivo Selective Inhibition of TRPC6 by Antagonist BI 749327 Ameliorates Fibrosis and Dysfunction in Cardiac and Renal Disease. *Proc. Natl. Acad. Sci. USA* 2019, 116, 10156–10161. [CrossRef] [PubMed]

105. Dragun, M.; Gažová, A.; Kyseľovíč, J.; Hulman, M.; Máňuš, M. TRP Channels Expression Profile in Human End-Stage Heart Failure. *Med. Kaunas Lith.* 2019, 55, 380. [CrossRef]
106. Tang, L.; Yao, F.; Wang, H.; Wang, X.; Shen, J.; Dai, B.; Wu, H.; Zhou, D.; Guo, F.; Wang, J.; et al. Inhibition of TRPC1 Prevents Cardiac Hypertrophy via NF-κB Signaling Pathway in Human Pluripotent Stem Cell-Derived Cardiomyocytes. *J. Mol. Cell. Cardiol.* 2019, 126, 143–154. [CrossRef]

107. Gronich, N.; Kumar, A.; Zhang, Y.; Efimov, I.R.; Soldatov, N.M. Molecular Remodeling of Ion Channels, Exchangers and Pumps in Atrial and Ventricular Myocytes in Ischemic Cardiomyopathy. *Channels* 2010, 4, 101–107. [CrossRef] [PubMed]

108. Eder, P. Cardiac Remodeling and Disease: SOCE and TRPC Signaling in Cardiac Pathology. *Adv. Exp. Med. Biol.* 2017, 993, 505–521. [CrossRef]

109. Tang, L.; Yao, F.; Wang, H.; Wang, X.; Shen, J.; Dai, B.; Wu, H.; Zhou, D.; Guo, F.; Wang, J.; et al. Inhibition of TRPC6 Channel Activity Contributes to the Antihypertrophic Effects of Natriuretic Peptides-Guanylyl Cyclase-Cys-1 Signaling in the Heart. *Circ. Res.* 2010, 106, 1849–1860. [CrossRef] [PubMed]

110. Cooley, N.; Grubb, D.R.; Luo, J.; Woodcock, E.A. The Phosphatidylinositol(4,5)Bisphosphate-Binding Sequence of Transient Receptor Potential Channel Canonical 4x Is Critical for Its Contribution to Cardiomyocyte Hypertrophy. *Mol. Pharmacol.* 2014, 86, 399–405. [CrossRef] [PubMed]

111. Camacho Londoño, J.E.; Tian, Q.; Hammer, K.; Schröder, L.; Camacho Londoño, J.; Reil, J.C.; He, T.; Oberhofer, M.; Mannebach, S.; Mathar, I.; et al. A Background Ca\(^{2+}\) Entry Pathway Mediated by TRPC1/TRPC4 Is Critical for Development of Pathologic Cardiac Remodelling. *Eur. Heart J.* 2015, 36, 2257–2266. [CrossRef] [PubMed]

112. Camacho Londoño, J.E.; Kuryshov, V.; Zorn, M.; Saar, K.; Tian, Q.; Hübner, N.; Nawroth, P.; Dietrich, A.; Birnbaumer, L.; Lipp, P.; et al. Transcriptional Signatures Regulated by TRPC1/C4-Mediated Background Ca\(^{2+}\) Entry after Pressure-Overload Induced Cardiac Remodelling. *Prog. Biophys. Mol. Biol.* 2021, 159, 86–104. [CrossRef] [PubMed]

113. Domes, K.; Patrucco, E.; Loga, F.; Dietrich, A.; Birnbaumer, L.; Wegener, J.W.; Hofmann, F. Murine Cardiac Growth, TRPC Channels, and CGMP Kinase I.* J. Phys. Arch.* 2015, 467, 2229–2234. [CrossRef] [PubMed]

114. Ma, T.; Lin, S.; Wang, B.; Wang, Q.; Xin, W.; Zhang, H.; Cui, Y.; He, C.; Wu, H.; Sun, F.; et al. TRPC3 Deficiency Attenuates High Salt-Induced Cardiac Hypertrophy by Alleviating Cardiac Mitochondrial Dysfunction. *Biochem. Biophys. Res. Commun.* 2019, 519, 674–681. [CrossRef]

115. Han, J.W.; Lee, Y.H.; Yoen, S.-I.; Abramowitz, J.; Birnbaumer, L.; Lee, M.G.; Kim, J.Y. Resistance to Pathologic Cardiac Hypertrophy and Reduced Expression of CaV1.2 in Trpc3-Depleted Mice. * Mol. Cell. Biochem.* 2016, 421, 55–65. [CrossRef]

116. Xie, Y.-P.; Chen, B.; Sanders, P.; Guo, A.; Li, Y.; Zimmerman, K.; Wang, L.-C.; Weiss, R.M.; Grumbach, I.M.; Anderson, M.E.; et al. Sildenafil Prevents and Reverses Transverse-Tubule Remodeling and Ca(2+) Handling Dysfunction in Right Ventricle Failure Induced by Pulmonary Artery Hyperension. *Hypertension 2012*, 59, 355–362. [CrossRef]

117. Seo, K.; Rainer, P.P.; Shalkay Hahn, V.; Lee, D.; Jo, S.-H.; Andersen, A.; Liu, T.; Xu, X.; Willette, R.N.; Lepore, J.J.; et al. Combined TRPC3 and TRPC6 Blockade by Selective Small-Molecule or Genetic Deletion Inhibits Pathological Cardiac Hypertrophy. *Proc. Natl. Acad. Sci. USA* 2014, 111, 1551–1556. [CrossRef]

118. Eder, P.; Molkentin, J.D. TRPC Channels as Effectors of Cardiac Hypertrophy. *Circ. Res.* 2011, 108, 265–272. [CrossRef]

119. Kiyonaka, S.; Kato, K.; Nishida, M.; Mio, K.; Numaga, T.; Sawaguchi, Y.; Yoshida, T.; Wakamori, M.; Mori, E.; Numata, T.; et al. Selective and Direct Inhibition of TRPC3 Channels Underlies Biological Activities of a Pyrazole Compound. *Proc. Natl. Acad. Sci. USA* 2009, 106, 5400–5405. [CrossRef]

120. Benoist, D.; Stones, R.; Benson, A.P.; Fowler, E.D.; Drinkhill, M.J.; Hardy, M.E.L.; Saint, D.A.; Cazorla, O.; Bernus, O.; White, E. Systems Approach to the Study of Stretch and Arrhythmias in Right Ventricular Failure Induced in Rats by Monocrotaline. *Proc. Bio. Mol. Biol.* 2014, 115, 162–172. [CrossRef]

121. Sabourin, J.; Boet, A.; Rucker-Martin, C.; Lambert, M.; Gomez, A.-M.; Benitah, J.-P.; Perros, F.; Humbert, M.; Antigny, F. Handling Remodeling and STIM1L/Orai1/TRPC1/TRPC4 Upregulation in Monocrotaline-Induced Right Ventricular Hypertrophy. *J. Mol. Cell. Cardiol.* 2018, 118, 208–224. [CrossRef] [PubMed]

122. Ohga, T.; Takezawa, R.; Arakida, Y.; Shimizu, Y.; Ishikawa, J. Characterization of YM-58483/BTP2, a Novel Store-Operated Ca\(^{2+}\) Entry Blocker, on T Cell-Mediated Immune Responses in Vivo. *Int. Immunopharmacol.* 2008, 8, 1787–1792. [CrossRef]

123. Zitt, C.; Strauss, B.; Schwarz, E.C.; Spaeth, N.; Rast, G.; Hatzelmann, A.; Hoth, M. Potent Inhibition of Ca\(^{2+}\) Release-Activated Ca\(^{2+}\) Channels and T-Lymphocyte Activation by the Pyrazole Derivative BTP2. *J. Biol. Chem.* 2004, 279, 12427–12437. [CrossRef] [PubMed]

124. Schreiter, H.; Doeschlal, B.; Lichtenegger, M.; Oppenrieder, R.; Derler, I.; Frischauf, I.; Glasnov, T.N.; Kappe, C.O.; Romanin, C.; Groschner, K. Novel Pyrazole Compounds for Pharmacological Discrimination between Receptor-Operated and Store-Operated Ca\(^{2+}\) Entry Pathways. *Br. J. Pharmacol.* 2012, 167, 1712–1722. [CrossRef] [PubMed]

125. Derler, I.; Schindl, R.; Fritsch, L.; Heitberger, P.; Riedl, M.C.; Begg, M.; House, D.; Romanin, C. The Action of Selective CRAC Channel Blockers Is Affected by the Orai Pore Geometry. *Cell Calcium* 2013, 53, 139–151. [CrossRef]

126. Di Sabatino, A.; Rovedatti, L.; Kaur, R.; Spencer, J.P.; Brown, J.T.; Morisset, V.D.; Biancheri, P.; Leakey, N.A.B.; Wilde, J.L.; Scott, L.; et al. Targeting Gut T Cell Ca\(^{2+}\) Release-Activated Ca\(^{2+}\) Channels Inhibits T Cell Cytokine Production and T-Box Transcription Factor T-Bet in Inflammatory Bowel Disease. *J. Immunol.* 2009, 183, 3454–3462. [CrossRef] [PubMed]

127. Waldherr, L.; Tiffner, A.; Mishra, D.; Sallinger, M.; Schober, R.; Frischauf, I.; Schmidt, T.; Handl, V.; Sagmeister, P.; Köckinger, M.; et al. Blockage of Store-Operated Ca\(^{2+}\) Influx by Synta66 Is Mediated by Direct Inhibition of the Ca\(^{2+}\) Selective Orai1 Pore. *Cancers* 2020, 12, 2876. [CrossRef]
128. Ng, S.W.; di Capite, J.; Singaravelu, K.; Parekh, A.B. Sustained Activation of the Tyrosine Kinase Syk by Antigen in Mast Cells Requires Local Ca\(^{2+}\) Influx through Ca\(^{2+}\) Release-Activated Ca\(^{2+}\) Channels. J. Biol. Chem. 2008, 283, 31348–31355. [CrossRef] [PubMed]

129. Sadaghiani, A.M.; Lee, S.M.; Odegaard, J.J.; Leveson-Gower, D.B.; McPherson, O.M.; Novick, P.; Kim, M.R.; Koehler, A.N.; Negrin, R.; Dolmetsch, R.E.; et al. Identification of Orai Channel Inhibitors by Using Minimal Functional Domains to Screen Small Molecule Microarrays. Chem. Biol. 2014, 21, 1278–1292. [CrossRef]

130. Masson, B.; Le Ribeuz, H.; Sabourin, J.; Laubry, L.; Woodhouse, E.; Foster, R.; Ruchon, Y.; Dutheil, M.; Boët, A.; Ghigna, M.-R.; et al. Orai Inhibitors as Potential Treatments for Pulmonary Arterial Hypertension. Circ. Res. 2022, 131, e109–e119. [CrossRef] [PubMed]

131. Kim, K.-D.; Srikanth, S.; Tan, Y.-V.; Yee, M.-K.; Jew, M.; Damaoiseaux, R.; Jung, M.E.; Shimizu, S.; An, D.S.; Ribalet, B.; et al. Calcium Signaling via Orai Is Essential for Induction of the Nuclear Orphan Receptor Pathway To Drive Th17 Differentiation. J. Immunol. 2014, 192, 110–122. [CrossRef] [PubMed]

132. Miller, J.; Bruen, C.; Schnaus, M.; Zhang, J.; Ali, S.; Lind, A.; Stoecker, Z.; Stauderman, K.; Hebarb, S. Auxora versus Standard of Care for the Treatment of Severe or Critical COVID-19 Pneumonia: Results from a Randomized Controlled Trial. Crit. Care 2020, 24, 502. [CrossRef] [PubMed]

133. CalciMedica, Inc. An Open-Label, Dose-Response Study of CM4620 Injectable Emulsion (CM4620-IE) in Patients with Acute Pancreatitis and Accompanying Systemic Inflammatory Response Syndrome (SIRS); CalciMedica, Inc.: La Jolla, CA, USA, 2019.

134. Rhizen Pharmaceuticals SA. A Phase I/IIa, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Safety, and Pharmacokinetics of Single and Multiple Ascending Dose of RP1328 in HV and Effect on LAR to Allergen Challenge in Mild Asthmatics. Rhizen Pharmaceuticals SA: Basel, Switzerland, 2019.

135. PRCL Research Inc. Randomized, Double Blind, Placebo Controlled, Incomplete Crossover Single Oral Dose Escalation of PRCL-02 in Normal Healthy Volunteers (Part A) and Multiple Oral Dose Escalation in Normal Healthy Volunteers (Part B) and in Chronic Plaque Psoriasis Patients (Part C); PRCL Research Inc.: Montreal, QC, Canada, 2018.

136. Stauderman, K.A. CRAC Channels as Targets for Drug Discovery and Development. Cell Calcium 2018, 74, 147–159. [CrossRef]

137. Rubaiy, H.N.; Ludlow, M.J.; Henrot, M.; Gaunt, H.J.; Miteva, K.; Cheung, S.Y.; Tanahashi, Y.; Hamzah, N.; Musialowski, K.E.; Blythe, N.M.; et al. Picomolar, Selective, and Subtype-Specific Small-Molecule Inhibition of TRPC1/4/5 Channels. J. Biol. Chem. 2017, 292, 8158–8173. [CrossRef] [PubMed]

138. Minard, A.; Bauer, C.C.; Wright, D.J.; Rubaiy, H.N.; Muraki, K.; Beech, D.J.; Bon, R.S. Remarkable Progress with Small-Molecule Signaling via Orai Is Essential for Induction of the Nuclear Orphan Receptor Pathway To Drive Th17 Differentiation. J. Immunol. 2014, 192, 110–122. [CrossRef] [PubMed]

139. Just, S.; Chenard, B.L.; Ceci, A.; Strassmaier, T.; Chong, J.A.; Blair, N.T.; Gallaschun, R.J.; del Camino, D.; Cantin, S.; D’Amours, M.; et al. Treatment with HC-070, a Potent Inhibitor of TRPC4 and TRPC5, Leads to Anxiolytic and Antidepressant Effects in Mice. PLoS ONE 2018, 13, e0191225. [CrossRef] [PubMed]

140. Miller, M.; Shi, J.; Zhu, Y.; Kustov, M.; Tian, J.; Stevens, A.; Wu, M.; Xu, J.; Long, S.; Yang, P.; et al. Identification of ML204, a Novel Potent Antagonist That Selectively Modulates Native TRPC4/C5 Ion Channels. J. Biol. Chem. 2011, 286, 33436–33446. [CrossRef] [PubMed]

141. Vinayagam, D.; Quentin, D.; Yu-Strezelczyk, Y.; Sitssel, O.; Merino, F.; Stabrin, M.; Hofnagel, O.; Yu, M.; Ledeboer, M.W.; Nagel, G.; et al. Structural Basis of TRPC4 Regulation by Calmodulin and Pharmacological Agents. eLife 2020, 9, e60603. [CrossRef]

142. Yu, M.; Ledeboer, M.W.; Daniels, M.; Malojcic, G.; Tabb, K.; Cottle-Keefe, E.; Fan, Y.; Westerling-Bui, A.; Beconi, M.; Reilly, J.F.; et al. Discovery of a Potent and Selective TRPC5 Inhibitor, Efficacious in a Focal Segmental Glomerulosclerosis Model. ACS Med. Chem. Lett. 2019, 10, 1579–1585. [CrossRef] [PubMed]

143. Washburn, D.G.; Holt, D.A.; Dodson, J.; Macon, J.; Terrell, L.R.; Barton, L.; Manns, S.; Waszkiewicz, A.; Pritchard, C.; Gillie, D.J.; et al. The Discovery of Potent Blockers of the Canonical Transient Receptor Channels, TRPC3 and TRPC6, Based on an Anilino-Thiazole Pharmacophore. Bioorg. Med. Chem. Lett. 2013, 23, 4979–4984. [CrossRef]

144. Häfner, S.; Burg, F.; Kannerl, M.; Urban, N.; Mayer, P.; Dietrich, A.; Trauner, D.; Broichhagen, J.; Schaefler, M. A (+)-Larixol Congener with High Affinity and Subtype Selectivity toward TRPC6. ChemMedChem 2014, 15, 1028–1035. [CrossRef]

145. Maier, T.; Follmann, M.; Hessler, G.; Kleemann, H.-W.; Hachtel, S.; Fuchs, B.; Weissmann, N.; Linz, W.; Schmidt, T.; Löh, M.; et al. Discovery and Pharmacological Characterization of a Novel Potent Inhibitor of Diacylglycerol-Sensitive TRPC Cation Channels. Br. J. Pharmacol. 2015, 172, 3650–3660. [CrossRef] [PubMed]

146. Bai, Y.; Yu, X.; Chen, H.; Horne, D.; White, R.; Wu, X.; Lee, P.; Gu, Y.; Ghimire-Rijal, S.; Lin, D.C.-H.; et al. Structural Basis for Pharmacological Modulation of the TRPC6 Channel. eLife 2020, 9, e53311. [CrossRef]

147. Walsh, L.; Reilly, J.F.; Cornwall, C.; Gaich, G.A.; Gipson, D.S.; Heerspink, H.J.L.; Johnson, L.; Trachtman, H.; Tuttle, K.R.; Farag, Y.M.K.; et al. Safety and Efficacy of GFB-887, a TRPC5 Channel Inhibitor, in Patients With Focal Segmental Glomerulosclerosis, Treatment-Resistant Minimal Change Disease, or Diabetic Nephropathy: TRACTION-2 Trial Design. Kidney Int. Rep. 2021, 6, 2575–2584. [CrossRef]

148. Zhao, Y.; McVeigh, B.M.; Moiseenko-Bell, V.Y. Structural Pharmacology of TRP Channels. J. Mol. Biol. 2021, 433, 166914. [CrossRef] [PubMed]

149. Li, J.; Zhang, X.; Song, X.; Liu, R.; Zhang, J.; Li, Z. The Structure of TRPC Ion Channels. Cell Calcium 2019, 80, 25–28. [CrossRef] [PubMed]